{"id":768317,"date":"2023-07-07T08:05:52","date_gmt":"2023-07-07T12:05:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\/"},"modified":"2023-07-07T08:05:52","modified_gmt":"2023-07-07T12:05:52","slug":"esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\/","title":{"rendered":"Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023"},"content":{"rendered":"
\n

ANN ARBOR, Mich., July 07, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced the presentation of a key abstract at the 2023 ASPC Congress on CVD Prevention taking place on July 21-23, 2023, in Arlington, TX.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Session Type:<\/td>\n\u00a0 \u00a0 \u00a0\u00a0<\/td>\n\u00a0Poster Session<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Date\/Time:<\/td>\n\u00a0<\/td>\nJuly 20, 2023: 2:00 \u2013 8:00 p.m. ET
July 21, 2023: 7:00 \u2013 9:30 a.m. ET<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Poster #:<\/td>\n\u00a0<\/td>\n136<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Abstract Title:<\/td>\n\u00a0<\/td>\n\n Background ezetimibe use among participants in the CLEAR Outcomes trial<\/em>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Location:<\/td>\n\u00a0<\/td>\nPoster Hall Area, Arlington Ballroom<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n
\n AND<\/u>
\n <\/strong>\n <\/td>\n		\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Session Type:<\/td>\n\u00a0<\/td>\nPoster Session – Author Q&A<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Date\/Time:<\/td>\n\u00a0<\/td>\nJuly 21, 2023: 11:35 a.m. \u2013 12:00 p.m. ET, 2:55 \u2013 3:10 p.m. ET, 5:40 \u2013 6:00 p.m. ET
July 22, 2023: 2:35 \u2013 2:50 p.m. ET
July 23, 2023: 10:40 \u2013 10:55 a.m. ET<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Presentation Title:<\/td>\n\u00a0<\/td>\n\n Background ezetimibe use among participants in the CLEAR Outcomes trial<\/em>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Location:<\/td>\n\u00a0<\/td>\nPoster Hall Area, Arlington Ballroom<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Presenter:<\/td>\n\u00a0<\/td>\nLuke Laffin, MD, Co-Director, Center for Blood Pressure Disorders at Cleveland Clinic<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n Esperion Therapeutics<\/strong>
\n
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol \u2013 that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life\u2019s work. For more information, visit esperion.com<\/a> and esperionscience.com<\/a> and follow us on Twitter at twitter.com\/EsperionInc.<\/a><\/p>\n

\n CLEAR Cardiovascular Outcomes Trial<\/strong>
\n
CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL\u00ae<\/sup> (bempedoic acid) Tablet and NEXLIZET\u00ae <\/sup>(bempedoic acid and ezetimibe) Tablet. The CLEAR Program seeks to generate important clinical evidence on the safety and efficacy of bempedoic acid, a first in a class ATP citrate lyase inhibitor contained in NEXLETOL and NEXLIZET and its potential role in addressing additional critical unmet medical needs. More than 60,000 people will have participated in the program by the time of its completion. The CLEAR Program includes 5 label-enabling Phase III studies as well as other key Phase IV studies with the potential to reach more than 70 million people with or at risk for CVD based on elevated LDL-C.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding regulatory submissions and potential approvals, marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its results, plans for potential future product candidates, financial condition and outlook, including expected cash runway, and other statements containing the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201csuggest,\u201d \u201ctarget,\u201d \u201cpotential,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccontinue,\u201d and similar expressions. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion\u2019s actual results to differ significantly from those projected, including, without limitation, the impact of the ongoing COVID-19 pandemic on our business, revenues, results of operations and financial condition, the net sales, profitability, and growth of Esperion\u2019s commercial products, clinical activities and results, supply chain, commercial development and launch plans, the outcomes of legal proceedings, and the risks detailed in Esperion\u2019s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.<\/p>\n

\n Esperion Contact Information:<\/strong>
\n
Investors:
Alexis Callahan
investorrelations@esperion.com<\/a>
(406) 539-1762<\/p>\n

Media:
Tiffany Aldrich
corporateteam@esperion.com<\/a>
(616) 443-8438<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

ANN ARBOR, Mich., July 07, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced the presentation of a key abstract at the 2023 ASPC Congress on CVD Prevention taking place on July 21-23, 2023, in Arlington, TX. Session Type: \u00a0 \u00a0 \u00a0\u00a0 \u00a0Poster Session \u00a0 \u00a0 \u00a0 Date\/Time: \u00a0 July 20, 2023: 2:00 \u2013 8:00 p.m. ETJuly 21, 2023: 7:00 \u2013 9:30 a.m. ET \u00a0 \u00a0 \u00a0 Poster #: \u00a0 136 \u00a0 \u00a0 \u00a0 Abstract Title: \u00a0 Background ezetimibe use among participants in the CLEAR Outcomes trial \u00a0 \u00a0 \u00a0 Location: \u00a0 Poster Hall Area, Arlington Ballroom \u00a0 \u00a0 \u00a0 AND \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Session Type: \u00a0 Poster Session – Author Q&A \u00a0 \u00a0 \u00a0 Date\/Time: \u00a0 July … <\/p>\n

Continue reading “Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-768317","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEsperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ANN ARBOR, Mich., July 07, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced the presentation of a key abstract at the 2023 ASPC Congress on CVD Prevention taking place on July 21-23, 2023, in Arlington, TX. Session Type: \u00a0 \u00a0 \u00a0\u00a0 \u00a0Poster Session \u00a0 \u00a0 \u00a0 Date\/Time: \u00a0 July 20, 2023: 2:00 \u2013 8:00 p.m. ETJuly 21, 2023: 7:00 \u2013 9:30 a.m. ET \u00a0 \u00a0 \u00a0 Poster #: \u00a0 136 \u00a0 \u00a0 \u00a0 Abstract Title: \u00a0 Background ezetimibe use among participants in the CLEAR Outcomes trial \u00a0 \u00a0 \u00a0 Location: \u00a0 Poster Hall Area, Arlington Ballroom \u00a0 \u00a0 \u00a0 AND \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Session Type: \u00a0 Poster Session – Author Q&A \u00a0 \u00a0 \u00a0 Date\/Time: \u00a0 July … Continue reading "Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-07T12:05:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzU5OCM1NjYyMjMwIzIwMDcxNDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023\",\"datePublished\":\"2023-07-07T12:05:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\\\/\"},\"wordCount\":654,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MzU5OCM1NjYyMjMwIzIwMDcxNDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\\\/\",\"name\":\"Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MzU5OCM1NjYyMjMwIzIwMDcxNDE=\",\"datePublished\":\"2023-07-07T12:05:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MzU5OCM1NjYyMjMwIzIwMDcxNDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MzU5OCM1NjYyMjMwIzIwMDcxNDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\/","og_locale":"en_US","og_type":"article","og_title":"Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023 - Market Newsdesk","og_description":"ANN ARBOR, Mich., July 07, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced the presentation of a key abstract at the 2023 ASPC Congress on CVD Prevention taking place on July 21-23, 2023, in Arlington, TX. Session Type: \u00a0 \u00a0 \u00a0\u00a0 \u00a0Poster Session \u00a0 \u00a0 \u00a0 Date\/Time: \u00a0 July 20, 2023: 2:00 \u2013 8:00 p.m. ETJuly 21, 2023: 7:00 \u2013 9:30 a.m. ET \u00a0 \u00a0 \u00a0 Poster #: \u00a0 136 \u00a0 \u00a0 \u00a0 Abstract Title: \u00a0 Background ezetimibe use among participants in the CLEAR Outcomes trial \u00a0 \u00a0 \u00a0 Location: \u00a0 Poster Hall Area, Arlington Ballroom \u00a0 \u00a0 \u00a0 AND \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Session Type: \u00a0 Poster Session – Author Q&A \u00a0 \u00a0 \u00a0 Date\/Time: \u00a0 July … Continue reading \"Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-07-07T12:05:52+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzU5OCM1NjYyMjMwIzIwMDcxNDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023","datePublished":"2023-07-07T12:05:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\/"},"wordCount":654,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzU5OCM1NjYyMjMwIzIwMDcxNDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\/","name":"Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzU5OCM1NjYyMjMwIzIwMDcxNDE=","datePublished":"2023-07-07T12:05:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzU5OCM1NjYyMjMwIzIwMDcxNDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzU5OCM1NjYyMjMwIzIwMDcxNDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-american-society-for-preventive-cardiology-aspc-congress-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/768317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=768317"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/768317\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=768317"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=768317"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=768317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}